Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 188-199

  de Rosa, Salvatore ^a   Cirillo, Plinio ^a   Pacileo, Mario ^a   Petrillo, Gianluca ^a   D'Ascoli, Greta Luana ^a   Maresca, Fabio ^a   Ziviello, Francesca ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Cardiovascular disease; Inflammation; Neopterin

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEOPTERIN; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CELL THERAPY; CORONARY ARTERY DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; MACROPHAGE; MOLECULE; NEPHRITIS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SYSTEMIC DISEASE; VIRUS INFECTION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; NEOPTERIN; PERIPHERAL ARTERIAL DISEASE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79951693944     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519372     Document Type: Article

References (144)

1. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009; 30: 2838-44.
2. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol 2010; 134: 5-24.
3. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010; 134: 33-46.
4. Keaney JF. Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction. Mol Aspects Med 2000; 21: 99-166.
5. Michael A, Gimbrone JR. Vascular endothelium: nature's bloodcompatible containera. Ann N Y Acad Sci 1987; 516: 5-11.
6. Ross R. Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am J Pathol 1993; 143: 987-1002.
7. Gimbrone MA, Jr. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol 1999; 155: 1-5.
8. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III-27-32.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
10. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002; 317: 1-15.
11. Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of Creactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for Health Care Professionals From the CRP Pooling Project Members. Stroke 2005; 36: 1316-29.
12. de Ferranti SD, Rifai N. C-reactive protein: a non-traditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007; 16: 14-21.
13. Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115: 981-9.
14. Kavsak PA, MacRae AR, Newman AM, et al. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem 2007; 40: 326-9.
15. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92: 17-22.
16. Cirillo P, Golino P, Calabro P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005; 68: 47-55.
17. De Rosa S, Cirillo P, Pacileo M, Di Palma V, Paglia A, Chiariello M. Leptin stimulated C-reactive protein production by human coronary artery endothelial cells. J Vasc Res 2009; 46: 609-17.
18. Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin 2008; 24: 75-8.
19. Gupta S, Fredericks S, Schwartzman R, Holt D, Kaski J. Serum neopterin in acute coronary syndromes. Lancet 1997; 349: 1252-3.
20. Schumacher M, Halwachs G, Tatzber F, et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997; 30: 703-7.
21. Auer J, Berent R, Lassnig E, Weber T, Eber B. Prognostic significance of immune activation after acute coronary syndromes. J Am Coll Cardiol 2002; 39: 1878-88.
22. Ray KK, Morrow DA, Sabatine MS, et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115: 3071-8.
23. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110: 1747-53.
24. Werner-Felmayer G, Werner ER, Fuchs D, et al. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem 1993; 268: 1842-6.
25. Huber C, Batchelor JR, Fuchs D, et al. Immune responseassociated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-6.
26. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307-41.
27. Manfred WZ, Benner Udo K, Zissel G, Zabel P, Schlaak MAX, Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-92.
28. Werner ER, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clin Chem 1987; 33: 62-6.
29. Katoh S, Sueoka T, Matsuura S, Sugimoto T. Biopterin and neopterin in human saliva. Life Sci 1989; 45: 2561-8.
30. Nathan C. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon-γ. London: Academic Press 1986; pp. 125-43.
31. Weiss G, Widner B, Zoller H, Schobersberger W, Fuchs D. Immune response and iron metabolism. Br J Anaesth 1998; 81: 6-9.
32. Anwaar I, Gottsater A, Hedblad B, Palmqvist B, Mattiasson I, Lindgarde F. Endothelial derived vasoactive factors and leukocyte derived inflammatory mediators in subjects with asymptomatic atherosclerosis. Angiology 1998; 49: 957-66.
33. Tatzber F, Rabl H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991; 89: 203-8.
34. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 457-63.
35. Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen risk and cardiovascular health study. Clin Chem 2009; 55: 1135-46.
36. Alber HF, Duftner C, Wanitschek M, et al. Neopterin, CD4+CD28- lymphocytes and the extent and severity of coronary artery disease. Int J Cardiol 2009; 135: 27-35.
37. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol 2004; 93: 627-9.
38. Vengen IT, Dale AC, Wiseth R, Midthjell K, Videm V. Neopterin predicts the risk for fatal ischemic heart disease in type 2 diabetes mellitus: long-term follow-up of the HUNT 1 study. Atherosclerosis 2009; 207: 239-44.
39. Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000; 83: 346-50.
40. Kaplan RC, McGinn AP, Baird AE, et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the women's health initiative observational study. J Stroke Cerebrovasc Dis 2008; 17: 344-55.
41. Sahin M, Varol E, Ozaydin M, et al. Comparison of neopterin levels in patients with coronary artery ectasia vs. patients with obstructive coronary artery disease. South Med J 2008; 101: 476-9.
42. Djordjevic V, Stojanovic I, Cosic V, et al. Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor alpha levels in patients with ischemic heart disease. Clin Chem Lab Med 2008; 46: 1149-55.
43. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000; 35: 956-62.
44. Tanaka T, Nakamura Y, Nasuno A, et al. Plasma concentrations of monocyte chemoattractant protein 1 (MCP-1) and neopterin in the coronary circulation of patients with coronary artery disease association with the severity of coronary atherosclerosis. Circ J 2004; 68: 114-20.
45. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M. Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction. Int J Cardiol 2006; 111: 318-20.
46. van Haelst PL, Liem A, van Boven AJ, et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003; 92: 1201-3.
47. Smith DA, Zouridakis EG, Mariani M, Fredericks S, Cole D, Kaski JC. Neopterin levels in patients with coronary artery disease are independent of chlamydia pneumoniae seropositivity. Am Heart J 2003; 146: 69-74.
48. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis 2008; 201: 176-83.
49. García-González MJ, Domínguez-Rodríguez A, Abreu-González P. Light-dark variations in neopterin serum levels in patients with STsegment elevation acute coronary syndrome undergoing primary angioplasty. Rev Esp Cardiol 2008; 61: 1280-6.
50. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315-22.
51. Abo T, Kawate T, Itoh K, Kumagai K. Studies on the bioperiodicity of the immune response. I. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood. J Immunol 1981; 126: 1360-3.
52. Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH. HMGCoA Reductase Inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. Clin Chem Lab Med 2003; 41: 1314-9.
53. Haelst PLv, Doormaal JJv, May JF, Gans ROB, Crijns HJGM, Tervaert JWC. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 2001; 12: 503-9.
54. Ridker P. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10: S9-12.
55. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atorvastatin suppresses interferon-gamma induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003; 131: 264-7.
56. Cirillo P, Pacileo M, De Rosa S, et al. HMG-CoA Reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells. J Vasc Res 2007; 44: 460-70.
57. Gottsäter A, Anwaar I, Lind P, Mattiasson I, Lindgärde F. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis 1999; 10: 133-40.
58. Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski J. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 2009; 16: 4644-53.
59. Adachi T, Naruko T, Itoh A, et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart 2007; 93: 1537-41.
60. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982; 66: 562-8.
61. Hammermeister KE. Survival in patients with coronary disease. Circulation 1979; 60: 1427.
62. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001; 6:95-103.
63. Bozkurt B, Kribbs SB, Clubb FJ, Jr., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-{alpha} promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382-91.
64. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001; 6: 71-80.
65. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-6.
66. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor- {alpha} and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
67. Margreiter R, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation 1983; 6: 650-3.
68. Balogh A, Mittermayr M, Schlager A, et al. Mechanism of neopterin- induced myocardial dysfunction in the isolated perfused rat heart. Biochim Biophys Acta 2005; 1724:17-22.
69. Wöll E, Weiss G, Fuchs D, Lang F, Wachter H. Effect of pteridine derivatives on intracellular calcium concentration in human monocytic cells. FEBS Lett 1993; 318: 249-52.
70. Hoffmann G, Gollnick F, Meyer R. Neopterin inhibits ATPinduced calcium release in alveolar epithelial cells in vitro. Mediators Inflamm 2002; 3: 181-5.
71. Barani J, Mattiasson I, Lindblad B, Gottsater A. Cardiac function, inflammatory mediators and mortality in critical limb ischemia. Angiology 2006; 57: 437-44.
72. Estévez-Loureiro R, Recio-Mayoral A, Sieira-Rodríguez-Moret JA, Trallero-Araguás E, Kaski JC. Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris. Atherosclerosis 2009; 207: 514-8.
73. Wietlicka-Kokoszanek I, Jablecka A, Smolarek I, et al. Neopterin as a prognostic marker in patients with chronic heart failure. Med Sci Monit 2010; 16: CR232-7.
74. Avanzas P, Arroyo-Espliguero R, Kaski JC. Neopterin -- Marker of coronary artery disease activity or extension in patients with chronic stable angina? Int J Cardiol 2010; 144: 74-5.
75. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, Laynez-Cerdeña I, Kaski JC. Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis 2010; 211: 574-8.
76. Rudzite V, Skards JI, Fuchs D, Reibnegger G, Wachter H. Serum kynurenine and neopterin concentrations in patients with cardiomyopathy. Immunol Lett 1992; 32: 125-9.
77. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113: 2623-9.
78. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106: 1420-5.
79. Barbaro G, Di Lorenzo G, Soldini M, et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 1999; 100: 933-9.
80. Sasaki T, Takeishi Y, Suzuki S, et al. High serum level of neopterin is a risk factor of patients with heart failure. Int J Cardiol 2010; 145: 318.
81. Caruso R, Trunfio S, Milazzo F, et al. Early expression of pro- and anti-inflammatory cytokines in left ventricular assist device recipients with multiple organ failure syndrome. ASAIO J 2010; 56: 313-8.
82. Arora S, Gunther A, Wennerblom B, et al. Systemic markers of inflammation are associated with cardiac allograft vasculopathy and an increased intimal inflammatory component. Am J Transplant 2010; 10: 1428-36.
83. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to Cytokine-Induced Myocardial Contractile Failure. Circ Res 2000; 87: 241-7.
84. Suematsu N, Tsutsui H, Wen J, et al. Oxidative Stress Mediates Tumor Necrosis Factor-{alpha}-Induced Mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003; 107: 1418-23.
85. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280: C53-60.
86. Peng J, Gurantz D, Tran V, Cowling RT, Greenberg BH. Tumor necrosis factor-_-induced AT1 receptor upregulation enhances angiotensin ii-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 2002; 91: 1119-26.
87. Aronow W. Peripheral arterial disease. Geriatrics 2007; 62: 19-25.
88. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-Reactive protein assay. Clin Chem 1999; 45: 2136-41.
89. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-43.
90. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003; 92: 194-9.
91. Tzoulaki I, Murray GD, Price JF, et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the edinburgh artery study. Am J Epidemiol 2006; 163: 334-41.
92. Hozawa A, Ohmori K, Kuriyama S, et al. C-reactive protein and peripheral artery disease among japanese elderly: the tsurugaya project. Hypertens Res 2004; 27: 955-61.
93. McDermott MM, Guralnik JM, Corsi A, et al. Patterns of inflammation associated with peripheral arterial disease: The InCHIANTI study. Am Heart J 2005; 150: 276-81.
94. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-Reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
95. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-5.
96. Barani J, Nilsson J-Å, Mattiasson I, Lindblad B, Gottsäter A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 2005; 42: 75-80.
97. Bertz L, Barani J, Gottsäter A, Nilsson P, Mattiasson I, Lindblad B. Are there differences of inflammatory bio-markers between diabetic and non-diabetic patients with critical limb ischemia? Int Angiol 2006; 25: 370-7.
98. Erren M, Reinecke H, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-63.
99. Garcia J, Kamijyo Y. Cerebral infarction. Evolution of histopathological changes after occlusion of a middle cerebral artery in primates. J Neuropathol Exp Neurol 1974; 33: 408-21.
100. Sörnäs R, Ostlund H, Müller R. Cerebrospinal fluid cytology after stroke. Arch Neurol 1972; 26: 489-501.
101. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-79.
102. Millner MM, Franthal W, Thalhammer GH, et al. Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin Chem 1998; 44: 161-7.
103. Grau AJ, Reis A, Buggle F, et al. Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 2001; 192: 41-7.
104. Emsley H, Smith C, Gavin C, et al. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol 2007; 7: 5.
105. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 2007; 26: 2211-21.
106. Cojocaru I, Cojocaru M, Burcin C, Atanasiu A. Detection of neopterin as parameter of potential monocyte activation in patients with acute ischemic stroke. Rom J Intern Med 2007; 45: 365-9.
107. Anwaar I, Gottsater A, Lindgarde F, Mattiasson I. Increasing plasma neopterin and persistent plasma endothelin during followup after acute cerebral ischemia. Angiology 1999; 50: 1-8.
108. Weiss G, Willeit J, Kiechl S, et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994; 106: 263-71.
109. Sugioka K, Naruko T, Hozumi T, et al. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris. Atherosclerosis 2009; 208: 524-30.
110. Shintani S, Murohara T, Ikeda H, et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001; 103: 897-903.
111. Kocher A, Schuster M, Szabolcs M, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 4: 430-6.
112. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222-32.
113. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-8.
114. Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute Myocardial Infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003; 108: 2212-8.
115. Aizawa S, Hiramoto M, Araki S, et al. Stimulatory effects of neopterin on hematopoiesis in vitro are mediated by activation of stromal cell function. Hematol Oncol 1998; 16: 57-67.
116. Zvetkova E, Gluhcheva Y, Fuchs D. Use of neopterin as a bone marrow hematopoietic and stromal cell growth factor in tissueengineered devices. Adv Exp Med Biol 2006: 115-21.
117. Fuchs D, Wachter H. Neopterin. In: Thomas L, Ed. Clinical laboratory diagnostics. Frankfurt: TH Verlagsgesellschaft 1998; pp. 707-10.
118. Shumakov V, Shevchenko O, Kazakov E, Orlova O, Gureev S, Makarova L. Prognostic value of C-reactive protein and neopterin in autologous bone marrow cells transplantation. Kardiologiia 2006; 46: 19-26.
119. Shumakov V, Shevchenko O, Orlova O, Onishchenko N, Gureev S. Inflammation and apoptosis in relation with the effectiveness of bone marrow cell transplantation to patients with chronic heart failure. Vestn Ross Akad Med Nauk 2006; 11: 14-21.
120. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production, tryptophan degradation, and mental depression- What is the link? Brain Behav Immun 2002; 16: 590-5.
121. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner E. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81-141.
122. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 8: 313-21.
123. Oettl K, Reibnegger G. Pteridine derivatives as modulators of oxidative stress. Curr Drug Metab 2002; 2: 203-9.
124. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Investig 2005; 115: 500-8.
125. De Rosa S, Cirillo P, Paglia A, Sasso L, Di Palma V, Chiariello M. Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? Curr Vasc Pharmacol 2010; 8: 259-75.
126. Nathan C, Prendergast T, Wiebe M, et al. Activation of human macrophages. Comparison of other cytokines with interferongamma. J Exp Med 1984; 2: 600-5.
127. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999; 4: 261-72.
128. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett 1995; 377: 461-4.
129. Murr C, Meinitzer A, Grammer T, et al. Association between asymmetric dimethylarginine and neopterin in patients with and without angiographic coronary artery disease. Scand J Immunol 2009; 70: 63-7.
130. Cirillo P, Pacileo M, De Rosa S, et al. Neopterin induces proatherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemostas 2006; 4: 2248-55.
131. Adams D, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 8901: 831-6.
132. Morisaki N, Saito I, Tamura K, et al. New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhe sion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis 1997; 131: 43-8.
133. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
134. Pawashe AB, Golino P, Ambrosio G, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63.
135. Ragni M, Cirillo P, Pascucci I, et al. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996; 93: 1913-8.
136. Hoffmann G, Schobersberger W, Frede S, et al. Neopterin activates transcription factor nuclear factor-[kappa]B in vascular smooth muscle cells. FEBS Lett 1996; 391: 181-4.
137. Barnes PJ, Karin M. Nuclear Factor-_B - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
138. Mackman N. Regulation of the tissue factor gene. Thromb Haemost 1997; 1: 747-54.
139. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
140. Yan Z-q, Sirsjo A, Bochaton-Piallat M-L, Gabbiani G, Hansson GK. Augmented expression of inducible NO synthase in vascular smooth muscle cells during aging is associated with enhanced NF- {kappa}B activation. Arterioscler Thromb Vasc Biol 1999; 19: 2854-62.
141. Noguchi T, Ishii K, Fukutomi H, et al. Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage. J Biol Chem 2008; 283: 7657-65.
142. Hsieh C-C, Papaconstantinou J. Thioredoxin-ASK1 complex levels regulate ROS-mediated p38 MAPK pathway activity in livers of aged and long-lived Snell dwarf mice. FASEB J 2006; 20: 259-68.
143. Soberanes S, Urich D, Baker CM, et al. Mitochondrial complex iiigenerated oxidants activate ASK1 and JNK to induce alveolar epithelial cell death following exposure to particulate matter air pollution. J Biol Chem 2009; 284: 2176-86.
144. Into T, Shibada K. Apoptosis signal-regulating kinase 1-mediated sustained p38 mitogen-activated protein kinase activation regulates mycoplasmal lipoprotein- and staphylococcal peptidoglycantriggered Toll-like receptor 2 signalling pathways. Cell Microbiol 2005; 7: 1305-17.